OBJECTIVE: To demonstrate the oncologic safety of transoral endoscopic laser surgery in early @entity5 . @entity1 : The study included 107 @entity1 with early @entity5 . The disease was in situ in 21 (19.6%) and infiltrative in 86 (80.4%), of which 52 (48.6%) were stage T1a, 17 (15.9%) were T1b, 13 (12.1%) were T2, and 4 (3.7%) were @entity75 . One hundred three @entity1 (96.3%) were treated primarily, whereas 4 @entity1 (3.7%) were operated on after radiotherapy failure. Anatomically, 77 lesions (72.0%) involved the anterior or middle third of the vocal cord; 14 lesions (13.1%) involved a single cord and the anterior commissure; 4 "horseshoe" lesions (3.7%) involved both cords and the anterior commissure; 7 lesions (6.5%) involved the posterior third of the cord reaching the vocal process of the arytenoid; and 5 cases (4.7%) involved both cords separately. RESULTS: There were 17 (15.9%) local recurrences (10 among @entity1 with single @entity602 , 5 among @entity1 with cord and anterior commissure lesions, and 2 among @entity1 with lesions involving both cords), and 1 regional recurrence. One hundred one @entity1 (94.4%) were alive and disease free at a median of 40.7 months. Three @entity1 (2.8%) were alive with disease. One @entity1 (0.9%) died of other causes. Two @entity1 (1.9%) died of a second @entity5 . The overall larynx preservation rate was 92.5%. Recurrence-free survival was 86.6% at 2 years, 84.1% at 5 years, and 78.1% at 10 years. CONCLUSION: Transoral laser surgery is an oncologically safe, function-preserving modality for treatment of early @entity5 .

Transoral laser surgery for early XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['primary cancer', 'glottic cancers'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity602 :: ('MESH:D013118', 'Disease') :: ['cord lesions'] @entity75 :: ('MESH:D001927', 'Disease') :: ['TX lesions']
@entity5 :: (MESH:D009369,Disease) :: ['glottic cancers']
